Metformin Alcohol Interaction Profile: What Drinkers on Metformin Need to Know

What the label says about alcohol and metformin

The drug interaction table in the immediate-release metformin hydrochloride label reads: 'Alcohol is known to potentiate the effect of metformin on lactate metabolism.' The instruction that follows is: 'Warn patients against excessive alcohol intake while receiving metformin hydrochloride tablets' [1]. The extended-release label carries the same entry [2].

Alcohol is not in the contraindications section, which lists severe renal impairment (eGFR below 30), hypersensitivity to metformin, and acute or chronic metabolic acidosis including diabetic ketoacidosis [1]. Alcohol sits in the warnings and in the boxed warning instead.

The boxed warning lists excessive alcohol intake among the risk factors for metformin-associated lactic acidosis, together with renal impairment, use of certain drugs such as carbonic anhydrase inhibitors, age 65 or older, radiologic contrast studies, surgery and other procedures, hypoxic states such as acute congestive heart failure, hepatic impairment and mitochondrial disease [1]. Metformin itself is a prescription biguanide labeled as an adjunct to diet and exercise for type 2 diabetes in adults and in children 10 and older (immediate-release) [1].

Why lactate is the issue

The label's explanation is short: metformin decreases liver uptake of lactate, which increases blood lactate levels and may increase the risk of lactic acidosis, especially in patients already at risk [1]. Alcohol, it says, potentiates that effect on lactate metabolism [1].

Reported cases of metformin-associated lactic acidosis were characterized by blood lactate above 5 mmol/L, anion gap acidosis without ketonuria or ketonemia, an increased lactate-to-pyruvate ratio, and metformin plasma levels generally above 5 mcg/mL [1].

How often does metformin-associated lactic acidosis happen?

This is a postmarketing finding covered by a boxed warning, and the label says the reported cases primarily occurred in patients with significant renal impairment [1]. A Cochrane systematic review pooled 347 comparative trials and cohort studies and found no fatal or nonfatal lactic acidosis in 70,490 patient-years of metformin use or in 55,451 patient-years of non-metformin therapy; using Poisson statistics, the upper limit for the true incidence was 4.3 cases per 100,000 patient-years with metformin and 5.4 without it [3].

The label says the risk of metformin accumulation rises with the severity of renal impairment because metformin is substantially excreted by the kidney [1]. It identifies kidney impairment, hepatic impairment and age 65 or older as risk factors for metformin-associated lactic acidosis [1].

Warning signs and what the label says to do

The boxed warning describes a subtle onset with nonspecific symptoms: malaise, myalgias, respiratory distress, somnolence and abdominal pain [1]. With severe acidosis, hypotension and resistant bradyarrhythmias have occurred [1].

The label directs that if lactic acidosis is suspected, metformin is discontinued and general supportive measures are instituted in a hospital setting, and that prompt hemodialysis is recommended to correct the acidosis and remove accumulated metformin; metformin is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions, and hemodialysis has often reversed symptoms [1]. The label also asks that patients and their families be taught these symptoms and told to stop the drug and report them if they occur [1].

Does alcohol add hypoglycemia risk on metformin?

The label's alcohol entry is about lactate, not glucose [1]. Its hypoglycemia warning is separate: combining metformin with insulin or an insulin secretagogue such as a sulfonylurea increases the risk of low blood sugar, and lower doses of those drugs may be required [1]. The label notes that with metformin, insulin secretion remains unchanged [1].

Who the label flags for extra caution

• Reduced kidney function. The label says to check eGFR before starting and at least yearly. It contraindicates metformin below 30, does not recommend starting at 30 to 45, says to reassess benefit and risk if eGFR later falls below 45, and says to discontinue if it falls below 30 [1].
• Age 65 or older. The label says risk rises with age because older patients are more likely to have hepatic, renal or cardiac impairment, and asks for more frequent renal assessment [1].
• Liver disease. The label says to avoid metformin in patients with clinical or laboratory evidence of hepatic disease, because cases of lactic acidosis have developed in patients with hepatic impairment; it says this may be due to impaired lactate clearance [1].
• Contrast imaging. For immediate-release metformin, the label says to stop treatment at the time of, or before, an iodinated contrast procedure in patients with eGFR 30 to 60, a history of hepatic impairment, alcoholism or heart failure, or when intra-arterial contrast is used, and to re-evaluate eGFR 48 hours afterward and restart only if renal function is stable [1].

Other points that matter for drinkers on metformin

B vitamins. The label carries a vitamin B12 warning: subnormal B12 levels occurred in about 7% of patients in 29-week trials, and the label asks for hematologic parameters annually and B12 every 2 to 3 years [1]. A 2026 review of B-vitamin deficiencies notes that alcohol consumption, bariatric surgery and metformin use are among the factors increasing these deficiencies in clinical practice, and that B12 deficiency leads to neuropathies and cognitive disorders [4]. The label says the B12 drop appears rapidly reversible with discontinuation of metformin or B12 supplementation [1].

Type of drink. The label's entry refers to alcohol in general; it draws no distinction between beer, wine and spirits [1].